- Home
- LUCD vs RNA Comparison
LUCD vs RNA Comparison
Compare LUCD & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | RNA |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.9M | 222.5M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LUCD | RNA |
|---|---|---|
| Price | $0.90 | $11.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 20 |
| Target Price | $4.13 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 764.8K | 208.8K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,346,000.00 | N/A |
| Revenue This Year | $115.58 | $88.12 |
| Revenue Next Year | $130.54 | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.86 | $10.75 |
| 52 Week High | $1.63 | $73.06 |
Technical Indicators
Market Signals| Indicator | LUCD | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 36.08 |
| Support Level | $0.88 | N/A |
| Resistance Level | $1.07 | $14.30 |
| Average True Range (ATR) | 0.05 | 0.78 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 6.12 | 17.18 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.